{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:14:38Z","timestamp":1737522878458,"version":"3.33.0"},"reference-count":18,"publisher":"Czech Society of Ophthalmology of the CzMA","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CSO"],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:p>Purpose: To analyze patients with optic disc drusen (ODD), with emphasis on modern diagnostics.\n\nMaterials and Methods: Research of the literature was conducted, together with a retrospective statistical analysis of patients with ODD. The group included individuals with ODD diagnosed using at least one of the following (ultrasound \u2013 USG, optical coherence tomography \u2013 OCT, fundus autofluorescence \u2013 FAF).\n\nResults: The group consisted of 12 patients (23 eyes), 7 women and 5 men. The mean age was 25 years. The mean observation period was 73 months. In total, 11 patients (22 eyes) had a bilateral finding and 1 patient (1 eye) had a unilateral finding. The mean age was 25 years. Buried drusen were confirmed in 69.6% of cases (8 patients, 16 eyes), superficial drusen were confirmed in 30.4% of cases (4 patients, 7 eyes). Mean best corrected visual acuity (BCVA) and mean intraocular pressure were stable over time (BCVA p = 0.236, IOP p = 0.855). The aforementioned diagnostic methods proved to be equally effective (p = 0.768). In 11 patients (21 eyes) a depression of the retinal nerve fiber layer (RNFL) was recorded. We found a statistically significant decrease of the RNFL over time in reference to the normative database in the superior temporal (p = 0.015), temporal (p = 0.026) and nasal segments (p = 0.011). After separation of superficial and buried drusen the same significant change was found in nasal segment in superficial drusen (p = 0,031). We found no statistically significant difference over time between superficial and buried drusen (p = 0.109\u20130.999 for individual segments).\n\nConclusion: ODD are common and visual functions remain stable. Their presence can be confirmed using modern paraclinical methods.<\/jats:p>","DOI":"10.31348\/2024\/39","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:01:55Z","timestamp":1737460915000},"page":"324-330","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Optic Disc Drusen Using Modern Imaging Paraclinical Methods"],"prefix":"10.31348","volume":"80","author":[{"given":"Michal","family":"B\u0159ez\u00edk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Kopeck\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Old\u0159ich","family":"Chrapek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juraj","family":"Timkovi\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"N\u011bm\u010dansk\u00fd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16213","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Daruich A, Bremond-Gignac D, Behar-Cohen F, Kermorvant E. R\u00e9tinopathie du pr\u00e9matur\u00e9: de la pr\u00e9vention au traitement [Retinopathy of prematurity: from prevention to treatment]. Med Sci (Paris). 2020 Oct;36(10):900-907. French. doi: 10.1051\/medsci\/2020163","DOI":"10.1051\/medsci\/2020163"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"de las Rivas Ram\u00edrez N, Luque Aranda G, Rius D\u00edaz F, et al. Risk factors associated with Retinopathy of Prematurity development and progression. Sci Rep. 2020;12:21977.","DOI":"10.1038\/s41598-022-26229-4"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hong EH, Shin YU, Cho H. Retinopathy of prematurity: a review of epidemiology and current tre-atment strategies. Clin Exp Pediatr. 2022 Mar;65(3):115-126. doi: 10.3345\/cep.2021.00773","DOI":"10.3345\/cep.2021.00773"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016\/j.ophtha.2021.05.031","DOI":"10.1016\/j.ophtha.2021.10.021"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wilkinson AR, Adams GGW, Fleck BW, Nieto-Hernandez R; Guideline Development Groups (GDG) of the Royal College of Paediatrics and Child Health (RCPCH) and the Royal College of Ophthalmo-logists (RCOphth). UK screening and treatment of retinopathy of prematurity Updated 2022 Gui-delines. Early Hum Dev. 2023 Mar;177-178:105715. doi: 10.1016\/j.earlhumdev.2023.105715","DOI":"10.1016\/j.earlhumdev.2023.105715"},{"key":"ref5","unstructured":"Kanski\u2019s Clinical Ophtalmology 2020; p.538."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-248; discussion 248-520.","DOI":"10.1093\/med\/9780190050726.003.0027"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Zobanov\u00e1 A, Brychc\u00ednov\u00e1 P, Autrata R, \u0160enkov\u00e1 K. Screening, Treatment and Long-term Observa-tion of Retinopathy of Prematurely Born Children in the Czech Republic. Cesk Slov Oftalmol. 2018;74(6):253-264.","DOI":"10.31348\/2018\/6\/7"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Strube YNJ, Wright KW. Pathophysiology of retinopathy of prematurity. Saudi J Ophthalmol. 2022 Oct 14;36(3):239-242. doi: 10.4103\/sjopt.sjopt_18_22","DOI":"10.4103\/sjopt.sjopt_18_22"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wood EH, Chang EY, Beck K, et al. 80 Years of vision: preventing blindness from retinopathy of prematurity. J Perinatol. 2021 Jun;41(6):1216-1224. doi: 10.1038\/s41372-021-01015-8","DOI":"10.1038\/s41372-021-01015-8"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Yucel OE, Eraydin B, Niyaz L, Terzi O. Incidence and risk factors for retinopathy of prematurity in premature, extremely low birth weight and extremely low gestational age infants. BMC Ophthal-mol. 2022 Sep 13;22(1):367. doi: 10.1186\/s12886-022-02591-9","DOI":"10.1186\/s12886-022-02591-9"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Dogra MR, Vinekar A. Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Tre-atment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Coun-tries. Pediatric Health Med Ther. 2023 Feb 15;14:59-69. doi: 10.2147\/PHMT.S391591","DOI":"10.2147\/phmt.s391591"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Enr\u00edquez AB, Avery RL, Baumal CR. Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity. Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):358-368. doi: 10.1097\/APO.0000000000000302","DOI":"10.1097\/apo.0000000000000302"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Sabri K, Ells AL, Lee EY, Dutta S, Vinekar A. Retinopathy of Prematurity: A Global Perspective and Recent Developments. Pediatrics. 2022 Sep 1;150(3):e2021053924. doi: 10.1542\/peds.2021-053924. PMID: 35948728","DOI":"10.1542\/peds.2021-053924"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Autrata R, Krejc\u00edrov\u00e1 I, Senkov\u00e1 K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. E J Ophthalmol. 2012 Sep-Oct;22(5):687-694. doi: 10.5301\/ejo.5000166","DOI":"10.5301\/ejo.5000166"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Fierson WM; American academy of pediatrics section on ophthalmology; american academy of ophthalmology; american association for pediatric ophthalmology and strabismus; american asso-ciation of certified orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018 Dec;142(6): e20183061. doi: 10.1542\/peds.2018-3061. Erratum in: Pe-diatrics. 2019 Mar;143(3)","DOI":"10.1542\/peds.2018-3810"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hartnett ME. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol. 2020 Oct; 218:208-213. doi: 10.1016\/j.ajo.2020.05.025, Erratum in: Am J Ophthalmol. 2021 Nov; 231:213","DOI":"10.1016\/j.ajo.2020.12.018"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Wang Z, Zhang Z, Wang Y, Di Y. Effect of ranibizumab on retinopathy of prematurity: A meta-analysis. Front Pharmacol. 2022 Aug 22; 13:897869. doi: 10.3389\/fphar.2022.897869","DOI":"10.3389\/fphar.2022.897869"}],"container-title":["Czech and Slovak Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:01:59Z","timestamp":1737460919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cs-ophthalmology.cz\/en\/journal\/articles\/341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2024,10,14]]}},"URL":"https:\/\/doi.org\/10.31348\/2024\/39","relation":{},"ISSN":["1805-4447","1211-9059"],"issn-type":[{"value":"1805-4447","type":"electronic"},{"value":"1211-9059","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}